文献速递糖尿病肥胖与代谢综合征

血清表面活性蛋白D作为肥胖2型糖尿病患者肺部受累的生物标志物

Serum Surfactant Protein D as a Biomarker for Measuring Lung Involvement in Obese Patients With Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

在门诊肥胖单元开展的病例对照研究纳入49例肥胖2型糖尿病患者与98例年龄、性别、体质指数及腰围匹配的非糖尿病受试者,检测血清SP-D与SP-A并评估肺功能。2型糖尿病患者血清SP-D较高(P=0.006),SP-A无差异;SP-D与FEV1呈负相关(r=-0.265;P=0.029),与残气量呈正相关(r=0.293;P=0.043)。

要点

  • 肥胖2型糖尿病患者血清SP-D高于匹配的非糖尿病对照(P=0.006),SP-A无差异。
  • 血清SP-D与FEV1负相关(r=-0.265;P=0.029),与残气量正相关(r=0.293;P=0.043)。
  • 识别FEV1占预计值<80%的最佳SP-D切点为132.3 ng/mL,曲线下面积0.725,敏感度77.7%,特异度69.4%。

核心结论

  • 血清SP-D浓度可能是检测肥胖2型糖尿病患者肺部损伤的有用生物标志物。

研究设计与样本

  • 在门诊肥胖单元开展的病例对照研究,纳入49例肥胖2型糖尿病患者和98例年龄、性别、体质指数及腰围匹配的非糖尿病受试者。
  • 采用酶联免疫吸附试验测定血清SP-D和SP-A水平,并评估用力肺量计和静态肺容积。

主要发现

  • 2型糖尿病患者血清SP-D浓度高于对照受试者(P=0.006),血清SP-A浓度无差异。
  • FEV1与血清SP-D呈负相关(r=-0.265;P=0.029),SP-D浓度与残气量呈显著正相关(r=0.293;P=0.043)。
  • 受试者工作特征分析显示,识别FEV1占预计值<80%的最佳SP-D切点为132.3 ng/mL(曲线下面积0.725;敏感度77.7%;特异度69.4%)。
  • 逐步多因素回归分析显示,血清SP-D浓度≥132.3 ng/mL与FEV1占预计值<80%独立相关(R2=0.406)。
  • 在所有受试者中,仅2型糖尿病的存在独立贡献于血清SP-D变异(R2=0.138)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Lung impairment is a new target for late diabetic complications. Biomarkers that could help identify patients requiring functional respiratory tests have not been reported. OBJECTIVE: Our aim was to examine whether serum surfactant protein D (SP-D) and A (SP-A) could be useful biomarkers of lung damage in obese patients with type 2 diabetes (T2D) without known lung disease. DESIGN AND SETTING: A case-control study conducted in an ambulatory obesity unit. PATIENTS: Forty-nine obese patients with T2D and 98 subjects without diabetes matched by age, sex, body mass index, and waist circumference were included. INTERVENTIONS: Serum SP-D and SP-A levels were measured using enzyme-linked immunosorbent assay. Forced spirometry and static pulmonary volume were assessed. RESULTS: Patients with T2D exhibited higher serum SP-D concentrations than control subjects (P = 0.006). No differences in serum SP-A concentrations were observed. There was an inverse association between forced expiratory volume in 1 second (FEV1) and serum SP-D (r = -0.265; P = 0.029), as well as a significant positive relationship between SP-D concentration and residual volume (r = 0.293; P = 0.043). From receiver operating characteristic analysis, the best SP-D cutoff to identify a FEV1 <80% of predicted was 132.3 ng/mL (area under the curve, 0.725; sensitivity, 77.7%; specificity, 69.4%). Stepwise multivariate regression analysis showed that serum SP-D concentration ≥132.3 ng/mL was independently associated with a FEV1 <80% of predicted (R2 = 0.406). Only the existence of T2D contributed independently to serum SD-P variance among all subjects (R2 = 0.138). CONCLUSIONS: Serum SP-D concentration can be a useful biomarker for detecting lung impairment in obese patients with T2D.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. López-Cano C, Lecube A, García-Ramírez M, et al. Serum Surfactant Protein D as a Biomarker for Measuring Lung Involvement in Obese Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2017. PMID: 28945872. doi:10.1210/jc.2017-00913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。